论文部分内容阅读
环孢素 A 对心脏移植后存活率产生重大影响,但排异仍是导致术后早期死亡主要原因。单克隆抗体 OKT_3能选择性地占用于 T 淋巴细胞表面 T_3抗原识别结构,因而能阻断 T 细胞的排异作用。1986年美国 FDA 批准用于肾移植后抗排异。近两年试用于心脏移植后效果亦令人满意,特别是对排异的预防作用。文中简述 OKT_3特性,用于心脏移植后抗排异的效果,副作用,抗体产生等问题,并分析其应用前景。
Cyclosporin A has a significant effect on the survival rate after cardiac transplantation, but rejection is still the main cause of early postoperative death. The monoclonal antibody OKT_3 can selectively occupy the T3 antigen-recognizing structure on the surface of T lymphocytes, thus blocking the rejection of T cells. In 1986, the US FDA approved anti-rejection after kidney transplantation. The effect of heart transplantation after two years of trials is also satisfactory, especially for the prevention of rejection. This article briefly describes the characteristics of OKT_3 for anti-rejection effects, side effects, and antibody production after heart transplantation, and analyzes its application prospects.